Black Diamond Therapeutics, Inc. BDTX is building its equity story around a single, high-leverage asset: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) ...

Redefining Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer in the Era of Novel Antibody-Drug Conjugates The following represents disclosure information provided by authors of this ...

Introduction Skin rash is the most common adverse effect in patients with cancer receiving epidermal growth factor receptor inhibitors (EGFRIs), which can impair quality of life and lead to treatment ...

Black Diamond Therapeutics, Inc. BDTX offers a high-leverage oncology setup built around one primary value driver: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor ...

5-Hydroxymethylated Biomarkers in Cell-Free DNA Predict Occult Colorectal Cancer up to 36 Months Before Diagnosis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial A two-arm ...

BDTX spotlights silevertinib's 86% CNS response in NSCLC, with 2026 durability data and a glioblastoma push shaping its brain-metastasis strategy.

New EGFR-targeting combos may improve response rates and durability for patients with head and neck cancer.

In a new study, clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) have demonstrated the use of exosomes to successfully target squamous cell cancer tumours that are ...

Nearly 40 years ago, researchers identified the epidermal growth factor (EGF) domain as a key component in mussel adhesive proteins. Since then, similar adhesive proteins have been discovered in a ...